Wenbo Yin

发表

Species-Selective Targeting of Fungal Hsp90: Design, Synthesis, and Evaluation of Novel 4,5-Diarylisoxazole Derivatives for the Combination Treatment of Azole-Resistant Candidiasis.

Hong Jiang, M. Cheng, Dongmei Zhao, 2022, Journal of medicinal chemistry.

Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.

Hong Jiang, M. Cheng, Dongmei Zhao, 2022, European journal of medicinal chemistry.

Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.

M. Cheng, Hong Jiang, Dongmei Zhao, 2021, European journal of medicinal chemistry.

Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects in vitro and in vivo.

M. Cheng, Dongmei Zhao, Chenzhou Hao, 2022, European journal of medicinal chemistry.

Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.

M. Cheng, Dongmei Zhao, Yin Sun, 2022, European journal of medicinal chemistry.

Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents

M. Cheng, Dongmei Zhao, Yin Sun, 2021, European Journal of Medicinal Chemistry.

Ligand-based pharmacophore modeling, virtual screening and biological evaluation to identify novel TGR5 agonists

Yang Zhao, Wei-Dong Chen, Yan-Dong Wang, 2021, RSC advances.

Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors.

M. Cheng, Dongmei Zhao, Yin Sun, 2021, European journal of medicinal chemistry.

Design, synthesis, and evaluation of novel 3,4‐isoxazolediamide derivatives for the combination treatment of azole‐resistant candidiasis

M. Cheng, Dongmei Zhao, Yin Sun, 2022, Archiv der Pharmazie.

Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs

Guoqi Zhang, M. Cheng, Dongmei Zhao, 2022, Journal of enzyme inhibition and medicinal chemistry.

Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.

M. Cheng, Hai-Tsang Huang, Dongmei Zhao, 2021, European journal of medicinal chemistry.

Identification of novel indole derivatives as highly potent and efficacious LSD1 inhibitors.

M. Cheng, Dongmei Zhao, Wenbo Yin, 2022, European journal of medicinal chemistry.

Discovery of 2,4‐diaminopyrimidine derivatives targeting p21‐activated kinase 4: Biological evaluation and docking studies

M. Cheng, Dongmei Zhao, Jing Guo, 2020, Archiv der Pharmazie.

Therapeutic potential of targeting LSD1/ KDM1A in cancers.

Dongmei Zhao, Wenbo Yin, Tianxiao Wu, 2021, Pharmacological research.

Discovery of 2-(4-Substituted-piperidin/piperazine-1-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-quinazoline-2,4-diamines as PAK4 Inhibitors with Potent A549 Cell Proliferation, Migration, and Invasion Inhibition Activity

Jian Wang, M. Cheng, Dongmei Zhao, 2018, Molecules.

Design, synthesis, and biological evaluation of aminopyridine derivatives as novel tropomyosin receptor kinase inhibitors

M. Cheng, Dongmei Zhao, Yin Sun, 2022, Archiv der Pharmazie.

Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold

M. Cheng, Dongmei Zhao, Yin Sun, 2022, European Journal of Medicinal Chemistry.

Novel bagasse cellulose-based foams with pH-responsive wetting properties for controlled oil/water separation

H Zhao, Wenbo Yin, Yang Liu, 2023, Industrial Crops and Products.

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.

Yinli Gao, Han-xun Wang, M. Cheng, 2022, European journal of medicinal chemistry.

Discovery of CZS-241: A Potent, Selective, and Orally Available Polo-Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia.

Han-xun Wang, M. Cheng, Dongmei Zhao, 2023, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.

M. Cheng, Dongmei Zhao, Yin Sun, 2022, European journal of medicinal chemistry.

Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.

M. Cheng, J. Gu, Tingting Wang, 2019, European journal of medicinal chemistry.

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists

Wei-Dong Chen, Yan-Dong Wang, W. Peng, 2021, RSC advances.

Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors.

Haitao Li, Jian Wang, M. Cheng, 2018, European journal of medicinal chemistry.

Discovery of the First Potent, Selective, and In Vivo Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of TRIM37-Amplified Breast Cancer.

Han-xun Wang, M. Cheng, Dongmei Zhao, 2023, Journal of medicinal chemistry.